ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Clinical trials for ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a pill combo outperform standard therapy for a Hard-to-Treat lung cancer?
Disease control Recruiting nowThis phase 3 trial is investigating whether a combination of two oral drugs, JAB-21822 and JAB-3312, can work better than the current standard treatment (immunotherapy plus chemotherapy) as a first-line therapy for people with advanced non-squamous non-small cell lung cancer that…
Matched conditions: ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Cancer-Fighting virus plus chemo and immunotherapy takes on lung cancer in new trial
Disease control Recruiting nowThis study tests a new approach for people with advanced lung cancer whose disease got worse after initial treatment. It combines an injected virus (Olvi-Vec) that targets cancer cells, followed by chemotherapy and an immunotherapy drug, and compares it to standard chemotherapy a…
Matched conditions: ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Genelux Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New antibody injection targets Hard-to-Treat lung cancer in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called TQB2922, given as a shot under the skin, in 42 people with advanced non-small cell lung cancer that has not responded to standard treatments. The drug is a bispecific antibody designed to block two cancer-related proteins (EGFR and c…
Matched conditions: ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC